Molecular screening program to select molecular-based recommended therapies for metastatic cancer patients: analysis from the ProfiLER trial
Olivier Trédan, Q. Wang, Daniel Pissaloux et al. · Annals of Oncology · 2019
Cited by 189 works. doi:10.1093/annonc/mdz080
Authors
- Olivier Trédan
- Daniel Pissaloux
- Philippe Alexandre Cassier
- Arnaud de la Fouchardière
- Jérôme Fayette
- Françoise Desseigne
- I. Ray-Coquard
- Christelle de la Fouchardière
- Didier Frappaz
- Pierre‐Etienne Heudel
- Alice Bonneville-Levard
- Aude Fléchon
- Matthieu Sarabi
- Pierre Guibert
- Thomas Bachelot
- Maurice Pérol
- Benoît You
- Nathalie Bonnin
- Olivier Collard
References
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
- Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations
- Tracking the Evolution of Non–Small-Cell Lung Cancer
- Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
- Integrating liquid biopsies into the management of cancer
- Pilot Study Using Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers
- Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative
- Biological and Therapeutic Impact of Intratumor Heterogeneity in Cancer Evolution
- High-Throughput Genomics and Clinical Outcome in Hard-to-Treat Advanced Cancers: Results of the MOSCATO 01 Trial